Cholangiocarcinoma Drug Pulled From Market, Other Options St

While the FDA approval of Truseltiq for FGFR2-positive cholangiocarcinoma was withdrawn, there are still other viable treatment options, an expert said.

Related Keywords

United States , American , Juan Valle , Cholangiocarcinoma Foundation , American Cancer Society , Drug Administration , American Cancer , New England Journal , Cholangiocarcinoma Becomes , Poster Child ,